| Autor: |
ZHAO Rongchang, YU Wenyan, FENG Yuxin, ZHANG Wanli, ZHU Chunrong |
| Jazyk: |
čínština |
| Rok vydání: |
2019 |
| Předmět: |
|
| Zdroj: |
Zhongliu Fangzhi Yanjiu, Vol 46, Iss 12, Pp 1123-1130 (2019) |
| Druh dokumentu: |
article |
| ISSN: |
1000-8578 |
| DOI: |
10.3971/j.issn.1000-8578.2019.19.0138 |
| Popis: |
Objective To conduct a meta-analysis on the data of S-1 and capecitabine or fluorouracil in the treatment of advanced colorectal cancer, to demonstrate the feasibility of S-1 replacing capecitabine or fluorouracil. Methods We searched published literature in the PubMed, Cochrane Library, Embase and CNKI databases, and searched for controlled trials at the Clinical Trials Center (https://www.clinicaltrials.gov/). The data extraction and quality evaluation were conducted according to Cochrane Handbook 5.1.0, and RevMan 5.3 software was used for the meta-analysis of relevant case-control studies. Results The data of 3462 patients from 11 randomized controlled trials were included. Compared with the capecitabine/fluorouracil regimen, OS was improved in the S-1 treatment group, but there was no statistically significant difference in PFS, DCR or ORR. The incidence of diarrhea, renal insufficiency and hand-foot syndrome in the S-1 group was lower than that in the control group. But the incidence of platelet reduction in the S-1 group was higher than that in the control group at a reasonable contrast dose. Conclusion S-1 has a certain therapeutic advantage after replacing capecitabine or fluorouracil in conventional chemotherapy on advanced colorectal cancer. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
